Stay updated on Abemaciclib Combinations in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Abemaciclib Combinations in Pancreatic Cancer Clinical Trial page.

Latest updates to the Abemaciclib Combinations in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page footer updates the site revision from v3.8.0 to v3.8.1; the study information remains unchanged.SummaryDifference0.0%

- Check8 days agoChange DetectedThe completed Phase 2 study record for abemaciclib, alone or in combination, in previously treated pancreatic ductal adenocarcinoma is available with its study design, eligibility criteria, outcomes, locations, and related research materials.SummaryDifference73%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH notice was added announcing a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision changed from v3.7.1 to v3.7.2, while the study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedA 403 Forbidden error page now appears, replacing the previous study record content with a standard access-denied screen. As a result, the detailed study information is no longer accessible on this page.SummaryDifference19%

Stay in the know with updates to Abemaciclib Combinations in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Abemaciclib Combinations in Pancreatic Cancer Clinical Trial page.